Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare clinical lab bidding demo

This article was originally published in The Gray Sheet

Executive Summary

CMS will soon announce the target region for its Medicare Clinical Lab Bidding Demonstration Project, as well as the date of a related bidder's conference, the agency says Oct. 9. The project is designed to assess the cost-saving potential of replacing Medicare's clinical laboratory fee schedule with prices based on the lowest bids from labs ("1The Gray Sheet" Aug. 13, 2007, p. 8). CMS has made three changes to the demo in response to comments received over the summer: Labs providing services exclusively to nursing home beneficiaries or those who receive home health services in the competitive bidding area will not be required to bid, but will be paid at the demonstration fee schedule rate; a non-winning lab may serve as a reference lab to those participating in the demo, but cannot bill Medicare directly; and the labs must bid on 303 Health Care Procedure Coding System (HCPCS) codes, representing the top 99% of tests paid for under the Part B Clinical Laboratory Fee Schedule. Various lab groups support legislation to quash the project ("2The Gray Sheet" Oct. 1, 2007, In Brief)

You may also be interested in...



Bill Would Stop Competitive Bidding Demonstration For Laboratory Services

A bill introduced in the House Aug. 4 would cancel a Medicare clinical laboratory services competitive bidding demonstration project before it begins

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel